Latest Conference Articles

Eating nutritiously is vital for all individuals, as it can reduce the risk of cancer and other debilitating diseases.

"Sudden death is 24 times more likely in someone with epilepsy than in the normal population," Elizabeth J. Donner, MD, assistant professor of neurology, University of Toronto said in her plenary lecture "Sudden Unexplained Death in Epilepsy."

In a striking case report, the stimulant modafinil was able to dramatically improve neurological functioning in an elderly woman suffering from bilateral thalamic infarction, a disorder that often is fatal.

Getting people who are having an acute stroke to the hospital in time for thrombolytic therapy appears to be thwarted by a variety of barriers, including the desire of a the patient to avoid being embarrassed an ambulance showing up at the front door.

Interviews with poster presenters at the American Academy of Neurology’s 61st Annual Meeting

Dr. Busis talks about the current health IT climate, AAN efforts to educate members about the use of health IT in practice, the recently passed HITECH Act, the importance of interoperability, future drivers of health IT adoption, and more.

The history of the neurologic examination, referral pattern among neurologists for neurointerventional procedures, Parkinson's disease on the Internet, and online learning are just a few of the many topics discussed during the Day 2 sessions at the AAN meeting.

In a wide-ranging review of the evidence base for the current standard of care for primary brain tumors and other central nervous system malignancies, Amy A. Pruitt, MD, touched on a variety of topics in neuro-oncology, including an overview of the epidemiology and diagnosis of primary brain tumors.

Here are 10 studies about Parkinson's disease which were among the hundreds cited by Susan H. Fox, MD, PhD, during her presentation on movement disorders at the 61st Annual Meeting of the American Academy of Neurology.

The "Guidelines, Practice, and Advocacy Open House Featuring Digital Demos" session had two things going for it that made it an easy choice for us to attend the and cover it for MDNG readers: 1) the tagline "Technology Solutions that You Can Afford" and 2) the triple bill of David Kibbe, MD; former MDNG: Neurology Edition Physician Editor-in-Chief Daniel Hier, MD, MBA, FAAN; and current MDNG: Neurology Edition Health IT Advisory Board member and columnist Steven Zuckerman, MD. The good doctors (and their colleagues) did not disappoint.

This debate featured Don Kemper, CEO of Healthwise, and Matthew Holt, co-founder of Health 2.0, LLC, discussing information therapy and Health 2.0, and why they thought one was better than the other.

It's the patient's job to manage his or her care, while the doctor's job is to provide the necessary tools and treatment.

Alternating mammography and MRI every 6 months appears to be the best way to detect cancer in high-risk women, an M.D. Anderson study found. This strategy can identify cancers not found by mammography alone, said Huong Le-Petross, MD, assistant professor, Diagnostic Radiology, who presented a retrospective pilot study at a poster session during the San Antonio Breast Cancer Symposium.

Previous studies have shown that the Oncotype DX Recurrence Score accurately estimates the risk of breast cancer recurrence in postmenopausal women with a diagnosis of invasive node-negative early stage estrogen-receptor–positive breast cancer who have undergone treatment with tamoxifen.

One of the primary goals in oncology research is finding ways to predict each woman’s individual risk of breast cancer.

Estimating survival for patients with early breast cancer for up to 15 years is possible, report researchers from Duke.

Herceptin plus docetaxel/cyclophosphamide (HER TC) adjuvant therapy—a non-anthracycline-containing regimen—was tolerable with acceptable safety for lower risk patients with HER2-positive early breast cancer, according to a large Phase II study.

Previous research indicates that dense breast tissue is a risk factor for breast cancer development. Some studies have suggested that women who have highly dense breasts (≥60%-75% dense tissue) were as much as six times more likely to develop carcinoma of the breast than women whose breasts consisted primarily of fatty tissue.

Tamoxifen, long considered the gold standard for treating estrogen-receptor (ER) positive, early-stage breast cancer, is known to increase the risk of thrombotic events (blood clots).

Researchers have released findings from a large retrospective study showing that women treated for early stage HER2-positive breast cancer tumors ≤ 1cm have a significantly greater risk of recurrence than women whose tumors are HER2-negative.

Although hormonal therapy with aromatase inhibitors is highly effective at preventing recurrence in menopausal women with breast cancer, several studies have shown that adherence leaves something to be desired.

Although the symposium focused on neurosurgery-specific content, it is still important that all neurologists are aware of the technological advancements in imaging, electrophysiology, and brain modeling that are happening all of the time.

Saturday night Robert Fisher, MD, professor of neurology and director of the Stanford Epilepsy Center, presented the first public results of the stimulation of the anterior nucleus of the thalamus in epilepsy (SANTE).

When physicians first realize they are being sued for malpractice, they feel %u201Cshame, anger, depression, a loss of control, and a crisis of confidence."

I was struck by the deep, eye-crossing complexity of it all, and the overwhelming potential for confusion and uncertainty generated by this process.